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Abstract An aggrecan G1-G2 substrate was used to determine
sites within the interglobular domain that were susceptible to
cleavage by MT1-MMP. Degradation products were identified
by Western blotting with neo-epitope antibodies specific for
MMP-derived N- and C-terminal sequences. The results showed
that MT1-MMP cleaved at the N341-F342 and D441-L442 bonds,
as shown for other MMPs, and also at a site 13 amino acids C-
terminal to the N341-F342 site. The G2 product of this additional
cleavage was identified by sequence analysis and revealed an N-
terminus commencing T355VxxPDVELPLP. The data are
consistent with MT1-MMP cleavage at three sites in the
aggrecan interglobular domain; one at N342-F342, a second at
D441-L442 and a third at Q354-T355.
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1. Introduction
Matrix metalloproteinases (MMPs) are important enzymes
involved in remodelling of the extracellular matrix under both
normal and pathological conditions. A number of MMPs is
expressed in cartilage and can be detected at elevated levels in
synovial £uids from arthritis patients, suggesting a role for
these enzymes in the cartilage destruction associated with joint
disease. Other studies have demonstrated increased levels of
MMPs in vitro under conditions where cartilage degradation
is stimulated by treatment with cytokines and retinoids.
Aggrecan is the major proteoglycan in cartilage and is es-
sential for tissue turgor and weight-bearing. Recent studies
utilising neo-epitope antibodies, speci¢c for the newly created
N- or C-termini of degraded fragments, have shown that
MMPs have a direct role in the proteolysis and subsequent
loss of aggrecan from cartilage in arthritis [1^5]. The predom-
inant site at which MMPs cleave in the aggrecan interglobular
domain (IGD) is between N341 and F342. The stromelysins,
collagenases, gelatinases, and matrilysin are all active at this
site [1,6^8]. MMP cleavage at N341-F342 produces aggrecan
fragments with N-terminal FFGVG... sequence and there is
evidence for cleavage at this site in vivo [1^5]. The major high-
buoyant-density aggrecan fragments found in human synovial
£uids from osteoarthritis (OA) and joint injury patients, how-
ever, do not correspond with MMP cleavage products, but
rather result from cleavage at the E373-A374 bond in the
IGD [9,10]. The putative enzyme responsible for this cleavage
is ‘aggrecanase’ but its identity is unknown.
Sato and co-workers identi¢ed a novel membrane-type
MMP (MT-MMP) by library screening and RT-PCR [11].
This ¢rst membrane-type MMP (MT1-MMP) was shown to
induce speci¢c activation of progelatinase A (MMP-2), thus
identifying a potentially critical mechanistic step in the regu-
lation of MMP activity in vivo. Subsequent studies have re-
vealed that MT1-MMP can also activate procollagenase-3
(MMP-13) and that progelatinase A considerably potentiates
this rate of activation [12]. Three additional membrane type
MMPs, MT2-MMP [13], MT3-MMP [14] and MT4-MMP
[15] have now been cloned. MT2-MMP and MT3-MMP are
also able to activate progelatinase A [16,17].
MT1-MMP is of particular interest since MT1-MMP
mRNA [18,19] and enzyme [18] are expressed in human OA
cartilage, and immunohistochemical studies have shown that
MT1-MMP localises to chondrocytes in the super¢cial and
transitional zones, corresponding with regions of cartilage
degradation [18]. MT1-MMP gene expression is also induced
by IL-1K and TNFK [18] both known to promote cartilage
degradation in vitro, but not by IL-1L [19]. In addition to its
progelatinase A activating activity, MT1-MMP exhibits clas-
sic collagenase activity by digesting ¢brillar collagens into
characteristic 3/4 and 1/4 fragments [20]. Fibronectin, vitro-
nectin, laminin, K1-proteinase inhibitor, K2-macroglobulin,
and aggrecan are also substrates for MT1-MMP [20,21]. In
this study we have determined the speci¢city of MT1-MMP
for aggrecan cleavage in the IGD. We report that MT1-MMP
cleaves at the N341-F342 bond, typical of all MMPs investi-
gated so far, at the D441-L442 bond cleaved by MMP-2, MMP-
7 and the collagenases and also at a novel site located approx-
imately half way between the major MMP site and the
E373sA374 aggrecanase site.
2. Materials and methods
Chemiluminescence blotting substrate kit and cysteine proteinase
inhibitor E-64 were from Boehringer Mannheim, Germany. Kerata-
nase (Pseudomonas sp.) (EC 3.2.1.103), keratanase II (Bacillus sp.) and
chondroitin ABC lyase (Proteus vulgaris) (EC 4.2.2.4) were from Sei-
kagaku Kogyo, Japan. Rabbit anti-mouse horseradish peroxidase
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(HRP) conjugated immunoglobulin was from Dako (Denmark). Poly-
vinylidene di£uoride (PVDF) membrane was from Micron Separa-
tions Inc. (Westborough, MA, USA). vMT1-MMP [22] was puri¢ed
as described previously [20]. ProMMP-2 was prepared from culture
media conditioned by human gingival ¢broblasts [23] and was a gen-
erous gift from Prof. G. Murphy, University of East Anglia, Norwich,
UK. Characterisation of monoclonal antibody AF-28 [24] and mono-
clonal antibody BC-3 [25] has been described. Characterisation of
polyclonal anti-VDIPEN antisera will be described elsewhere. All oth-
er reagents were of analytical grade.
2.1. Enzyme digestions
MMP digestions were in bu¡er containing 10 mM calcium chloride,
100 mM sodium chloride, 50 mM Tris-HCl, pH 7.5, for 16 h at 37‡C,
and were stopped by the addition of EDTA and 1,10-phenanthroline
to ¢nal concentrations of 10 mM and 2 mM, respectively. Digested
samples were treated with keratanase prior to analysis by SDS-PAGE.
Keratanase digestions were in 50 mM Tris-acetate bu¡er, pH 7.2, at
37‡C overnight with 0.02 units of keratanase/30 Wl, in the presence of
10 mM EDTA, 20 Wg/ml E64, 5 WM pepstatin and 1.25 mM AEBSF.
2.2. N-terminal sequence analysis of MT1-MMP digested G1-G2
For sequencing experiments, 150 Wg G1-G2 was digested with
35.5 Wg/ml vMT1-MMP for 24 h at 37‡C in 10 mM calcium chloride,
100 mM sodium chloride, 50 mM Tris-HCl, pH 7.5. The sample was
not treated with EDTA, 1,10-phenanthroline or keratanase but imme-
diately freeze-dried, electrophoresed on 5% SDS gels [26] and trans-
ferred to PVDF membrane. G1-G2 fragments were visualised by
staining with methylene blue and excised bands analysed on a Procise
491 Protein Sequencer (Perkin-Elmer, USA).
2.3. Western blot analysis
Samples electrophoresed on 5% SDS gels were transferred to PVDF
membrane and analysed for AF-28 epitope (1:1000), ...DIPEN epit-
ope (1:1000) and BC-3 epitope (1:1000). Monoclonal AF-28 detects
the N-terminal FFGVG... sequence present on IGD fragments de-
rived from MMP cleavage [24]. Polyclonal anti-DIPEN detects the
C-terminal ...DIPEN sequence present on G1 fragments derived
from MMP cleavage. Monoclonal BC-3 detects the N-terminal
ARGSV... sequence present on IGD fragments derived from aggreca-
nase cleavage [25]. Prior to immunodetection with BC-3, glycos-
aminoglycan chains were removed by digesting the membrane with
0.01 U/ml chondroitin ABC lyase, 0.01 U/ml keratanase and 0.001 U/
ml keratanase II in 50 mM Tris-acetate, pH 7.4, for 2 h at room
temperature [25].
3. Results
3.1. Digestion of G1-G2 with vMT1-MMP and MMP-2
An aggrecan G1-G2 substrate [27] was digested with
vMT1-MMP and MMP-2, separately and in combination,
to determine the ability of vMT1-MMP to cleave aggrecan
in the IGD. The pattern of digestion products was analysed
by SDS-PAGE with silver staining, and fragments identi¢ed
by Western blotting (Fig. 1). Each band in Fig. 1 has been
numbered and the fragments represented schematically in Fig.
2. MMP-2 digestion of G1-G2 without vMT1-MMP (Fig. 1a,
lane 4), yielded a 50-kDa G1 product (fragment 1) and an 85-
kDa G2 product (fragment 2), as seen by silver stain. These
products have been characterised previously for MMP-2 [7]
and several other MMPs [6,7,24,28,29]. When vMT1-MMP
was included with MMP-2 in the digests (Fig. 1a, lanes 5
and 6), a third band, fragment 3, was visible by silver stain.
The size of fragment 3 was comparable with the size of small
G2 products from MMP-13 [29] and MMP-8 [30] digests.
Digestion of G1-G2 with vMT1-MMP in the absence of
MMP-2 (Fig. 1a, lanes 2 and 3) produced G1 domain (frag-
ment 1), a small amount of the large G2 domain (fragment 2),
and signi¢cant amounts of fragment 3. This pattern of silver-
stained fragments suggests that vMT1-MMP cleaves at
PEN341sFFG to generate fragments 1 and 2, and also at
another site in the IGD to generate fragment 3. The results
show that fragment 3 is a product of vMT1-MMP digestion,
but not MMP-2 digestion.
Immunoblotting with polyclonal antisera speci¢c for the
...DIPEN C-terminus revealed a single band of approximately
57 kDa in both the vMT1-MMP and MMP-2 digested sam-
ples (Fig. 1b). These results show that vMT1-MMP cleaves
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Fig. 1. Digestion of G1-G2 with MT1-MMP and MMP-2. Puri¢ed
pig G1-G2 was digested for 16.5 h at 37‡C with 9.9 Wg/ml (lanes 2
and 5) or 35.5 Wg/ml (lanes 3 and 6) MT1-MMP. MMP-2 was in-
cluded in lanes 5 and 6, at a ¢nal concentration of 13 Wg/ml. Lane
4: MMP-2 alone at 13 Wg/ml. Samples were electrophoresed on 5%
SDS gels and analysed by silver stain (a), or Western blotting with
anti-...DIPEN antisera (b), or monoclonal antibody AF-28 (c). c:
AF-28 immunoreactive bands developed with chemiluminescence re-
agent were exposed to X-ray ¢lm for either 10 s (upper panel) or
5 min (lower panel).
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the N341-F342 bond in the IGD to generate a G1 fragment
with a ...DIPEN C-terminus.
AF-28 immunoblotting of the MMP-2 digested G1-G2
showed two major products (Fig. 1c, upper panel, lane 4).
The largest band represents the same 85-kDa G2 band that
was detected by silver stain, and is therefore fragment 2. A
proportion of AF-28 epitope was present as a band of ap-
proximately 68 kDa, and is labelled fragment 6. Based on its
size and N-terminal sequence, this band most likely corre-
sponds with a fragment derived from the interglobular do-
main that is the product of cleavage at both the major
(PEN341sFFG) and minor (SED441sLVV) MMP cleavage
sites, and has been described previously [8,24,30]. Note that
fragment 3, which is approximately the same size but lacks the
AF-28 epitope is readily detected by silver stain because of its
G2 globular domain. Fragment 6 on the other hand is readily
detected by AF-28 but poorly detected by silver stain because
it lacks a globular domain.
When the AF-28 immunoblot was allowed to develop with
the ECL reagent for a longer period of time (Fig. 1c, lower
panel), a low molecular weight AF-28 band was seen in sam-
ples digested with vMT1-MMP, with and without MMP-2,
but not in samples digested with MMP-2 only. This fragment
with its F342FGVG... N-terminus has been labelled fragment
5. The most likely interpretation of the data is that fragment 5
represents the N-terminal portion of fragment 2, which is
cleaved by vMT1-MMP to produce fragment 3 (Fig. 2). To
determine whether vMT1-MMP was able to hydrolyse the E-
A bond, Western blots were carried out with monoclonal BC-
3, speci¢c for the ARGSVI... N-terminus on aggrecanase-de-
rived fragments. No bands were detected with monoclonal
BC-3 (data not shown).
3.2. N-terminal sequence analysis of the vMT1-MMP
digestion product
N-terminal sequencing of fragment 3 was done in order to
identify which peptide bond in the IGD was cleaved by
vMT1-MMP to produce fragments 3 and 5. The analysis
revealed that the N-terminus of fragment 3 was
TVxxPDVELPLP, corresponding to vMT1-MMP cleavage
at Q354sT355. This novel cleavage site in the aggrecan IGD
has not been reported for other MMPs or any proteinase Fig.
3.
4. Discussion
The localisation of MT1-MMP to areas of articular carti-
lage undergoing resorption in OA tissue has highlighted the
potential role of this enzyme in joint pathology [18]. In addi-
tion to the involvement of aggrecanase in arthritic disease
[9,10,31], there is also signi¢cant involvement of one or
more MMPs in aggrecan degradation. MMP inhibitors can
speci¢cally block release of aggrecan from resorbing cartilage
[32^34] but more compelling evidence for MMP involvement
is that N- and C-terminal aggrecan neo-epitope sequences
have been found in cartilage by sequencing [1] and immuno-
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Fig. 3. MMP and proteinase cleavage sites in the aggrecan IGD. A portion of the proteinase-sensitive amino acid sequence (human [39]) lo-
cated between the G1 and G2 domains of aggrecan is shown and includes the known cleavage sites for MMPs, plasmin, urokinase, cathepsin
B and elastase.
Fig. 2. Products of MT1-MMP cleavage of aggrecan G1-G2. Sche-
matic representation of aggrecan G1-G2 substrate showing the
products of vMT1-MMP digestion, identi¢ed by Western blotting
(fragments 1, 2, 5 and 6), sequence analysis (fragment 3), or pre-
dicted (fragment 4). Fragment 4 is predicted based on identi¢cation
of fragment 6, and in comparison with the products of MMP-1, -7
and -8 digestion [7,8,30].
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localisation [2,4,5] experiments, and in synovial £uids by im-
munoassay [3]. Since MT1-MMP shares the same sequence
speci¢city for cleavage at N341sF342 as other members of
the MMP family, it must be considered as one of the candi-
date mediators of aggrecan degradation.
The cleavage at Q354sT355 by MT1-MMP occurred 13 ami-
no acids C-terminal to the major N341sF342 site. Detection of
threonine in the ¢rst sequencing cycle shows that T355 is not
substituted with keratan sulphate or other O-linked oligosac-
charides in pig laryngeal aggrecan. However, T357 at cycle
three was not detected, suggesting that this amino acid may
be substituted with keratan sulfate as has been shown for
aggrecan from bovine articular cartilage [35].
Cleavage at Q354sT355 appears to be more substantial than
the secondary cleavages at S377sV378, E373sA374 and
P384sV385 by MMP-3 [30], MMP-8 [30] and MMP-13 [29],
respectively. High in vitro concentrations of MMP-3, MMP-
8 and MMP-13 were required to achieve cleavage at these
minor sites, and the products were present in correspondingly
minor amounts. Furthermore cleavage at the minor sites oc-
curred subsequent to complete cleavage at N341sF342. In con-
trast, for DMT1-MMP digestions, a signi¢cant proportion of
fragment 3 was produced concomitantly with production of
G1 and the 85-kDa G2 fragment, and with only partial cleav-
age of the native G1-G2 substrate (Fig. 1a, lane 2), suggesting
that there is no requirement by MT1-MMP for a prior cleav-
age at N341sF342. Buºttner et al. using an arti¢cial recombi-
nant substrate rAgg1 [36], have also shown that compared
with MMP-3 and MMP-8, cleavage at the N341sF342 site by
MT1-MMP was signi¢cantly less [37].
Although the molecular identity of aggrecanase is un-
known, MMP-8 [30] and the snake venom metalloproteinase
atrolysin C [38] have been shown to cleave at the E373sA374
aggrecanase site in the IGD. We were unable to detect aggre-
canase products in MT1-MMP digests of G1-G2, by sequenc-
ing or by BC-3 Western blotting, in contrast to Buºttner et al.
who found that MT1-MMP generated BC-3 epitope following
cleavage of the rAgg1 substrate [37]. The discrepancy in the
results may re£ect the source of recombinant enzymes or the
nature of the substrates.
Whether MT1-MMP cleaves aggrecan in vivo is not known.
Some AF-28 fragments detected in human synovial £uids are
of a size similar to fragment 5 [3]. Because these small AF-28
fragments lack the ...ITEGE373 C-terminus, an enzyme other
than aggrecanase must be cleaving in close proximity to the
aggrecanase site. Further work is needed to determine whether
cleavage by MT1-MMP at Q354sT335 generates fragments of
this type in human disease.
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